BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 15812225)

  • 1. Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver.
    Ohashi K; Nakai H; Couto LB; Kay MA
    Hum Gene Ther; 2005 Mar; 16(3):299-306. PubMed ID: 15812225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.
    Nakai H; Yant SR; Storm TA; Fuess S; Meuse L; Kay MA
    J Virol; 2001 Aug; 75(15):6969-76. PubMed ID: 11435577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction.
    Miao CH; Nakai H; Thompson AR; Storm TA; Chiu W; Snyder RO; Kay MA
    J Virol; 2000 Apr; 74(8):3793-803. PubMed ID: 10729154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis.
    Zabaleta N; Salas D; Paramo M; Hommel M; Sier-Ferreira V; Hernandez-Alcoceba R; Prieto J; Bilbao JI; Gonzalez-Aseguinolaza G
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):68-73. PubMed ID: 28285544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
    Manno CS; Pierce GF; Arruda VR; Glader B; Ragni M; Rasko JJ; Ozelo MC; Hoots K; Blatt P; Konkle B; Dake M; Kaye R; Razavi M; Zajko A; Zehnder J; Rustagi PK; Nakai H; Chew A; Leonard D; Wright JF; Lessard RR; Sommer JM; Tigges M; Sabatino D; Luk A; Jiang H; Mingozzi F; Couto L; Ertl HC; High KA; Kay MA
    Nat Med; 2006 Mar; 12(3):342-7. PubMed ID: 16474400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction.
    Nakai H; Thomas CE; Storm TA; Fuess S; Powell S; Wright JF; Kay MA
    J Virol; 2002 Nov; 76(22):11343-9. PubMed ID: 12388694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.
    Müller OJ; Leuchs B; Pleger ST; Grimm D; Franz WM; Katus HA; Kleinschmidt JA
    Cardiovasc Res; 2006 Apr; 70(1):70-8. PubMed ID: 16448634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
    Liu YL; Mingozzi F; Rodriguéz-Colôn SM; Joseph S; Dobrzynski E; Suzuki T; High KA; Herzog RW
    Hum Gene Ther; 2004 Aug; 15(8):783-92. PubMed ID: 15319035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo.
    Ren C; Kumar S; Shaw DR; Ponnazhagan S
    Hum Gene Ther; 2005 Sep; 16(9):1047-57. PubMed ID: 16149903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.
    Ding Z; Georgiev P; Thöny B
    Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors.
    Song S; Embury J; Laipis PJ; Berns KI; Crawford JM; Flotte TR
    Gene Ther; 2001 Sep; 8(17):1299-306. PubMed ID: 11571566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors.
    Raake PW; Hinkel R; Müller S; Delker S; Kreuzpointner R; Kupatt C; Katus HA; Kleinschmidt JA; Boekstegers P; Müller OJ
    Gene Ther; 2008 Jan; 15(1):12-7. PubMed ID: 17943147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.
    Mingozzi F; Schüttrumpf J; Arruda VR; Liu Y; Liu YL; High KA; Xiao W; Herzog RW
    J Virol; 2002 Oct; 76(20):10497-502. PubMed ID: 12239326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes.
    Dane AP; Wowro SJ; Cunningham SC; Alexander IE
    Gene Ther; 2013 Apr; 20(4):460-4. PubMed ID: 22895507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype.
    Grimm D; Pandey K; Nakai H; Storm TA; Kay MA
    J Virol; 2006 Jan; 80(1):426-39. PubMed ID: 16352567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction.
    Gernoux G; Guilbaud M; Dubreil L; Larcher T; Babarit C; Ledevin M; Jaulin N; Planel P; Moullier P; Adjali O
    Hum Gene Ther; 2015 Jan; 26(1):1-13. PubMed ID: 25333770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
    Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
    Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.